Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

NCT03880877 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

153

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Regorafenib
GENETIC: UGT1A1 genotyping (TA6/TA6)
GENETIC: UGT1A1 genotyping (TA6/TA7)
GENETIC: UGT1A1 genotyping (TA7/TA7)
DRUG: Leucovorin and 5-FU

Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital